Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589462 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL1051987 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30824576 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL29394965 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL839974 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL839730 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL839085 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL1764675 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30008129 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30812563 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220290197-A1 | TRANSAMINASE REACTIONS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-09-15 | — | — | US | claimed |
| CN-110036009-A | Substituted pyrrolidines and their use in the treatment of cystic fibrosis | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | claimed |
| US-10138503-B2 | Transaminase reactions | CODEXIS, INC. (US) | 2018-11-27 | — | — | US | claimed |
| EP-2446026-B1 | TRANSAMINASE REACTIONS | CODEXIS INC (US) | 2017-08-09 | — | — | EP | claimed |
| US-20160333381-A1 | TRANSAMINASE REACTIONS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | claimed |
| US-9434968-B2 | Transaminase reactions | CODEXIS, INC. (US) | 2016-09-06 | — | — | US | claimed |
| US-20150079640-A1 | TRANSAMINASE REACTIONS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-03-19 | — | — | US | claimed |
| US-8921079-B2 | Transaminase reactions | CODEXIS, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20120190085-A1 | Transaminase Reactions | CODEXIS, INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2446026-A1 | TRANSAMINASE REACTIONS | Codexis, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| WO-2011005477-A1 | TRANSAMINASE REACTIONS | CODEXIS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-12247233-B2 | Transaminase reactions | CODEXIS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | CHRM5 4880/4885CHRM3 4877/4885CHRM2 4863/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | CHRM5 4880/4885CHRM3 4877/4885CHRM2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.